{"id":103529,"date":"2023-09-22T20:44:56","date_gmt":"2023-09-22T20:44:56","guid":{"rendered":"https:\/\/dailytalks.org\/?p=103529"},"modified":"2023-09-22T20:44:56","modified_gmt":"2023-09-22T20:44:56","slug":"european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=103529","title":{"rendered":"European Medicines Agency Accepts Astellas&#8217; Marketing Authorization Application for Zolbetuximab"},"content":{"rendered":"<p>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \u201cAstellas\u201d) today announced the European Medicines Agency (EMA) has accepted for regulatory review the company&#8217;s marketing authorization application (MAA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tum&#8230;Read the full story at <a href=\"https:\/\/www.webwire.com\/ViewPressRel.asp?aId=308077\" target=\"_blank\" rel=\"noopener\">https:\/\/www.webwire.com\/ViewPressRel.asp?aId=308077<\/a>&#8230;<br \/><a href=\"https:\/\/www.webwire.com\/ViewPressRel.asp?aId=308077\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \u201cAstellas\u201d) today announced the European<\/p>\n","protected":false},"author":1,"featured_media":103530,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-103529","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103529-european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab.jpg",240,240,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/103529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=103529"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/103529\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/103530"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=103529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=103529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=103529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}